Drugs.com
Researchers in Seoul found 10-year cancer rates rose from 1.8% at normal weight to 2.6% with severe obesity, with belly fat showing the highest rates.
Recap by typeshit. Full story at Drugs.com.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
Omer Raheem says he presented his team's work on GLP-1 therapies past weight loss at the ISSM Journals Webinar 2026.
The rundown covers CagriSema, retatrutide, MariTide, VK2735 and Roche's enicepatide, which the company says cut weight by 15.5% on average in a mid-stage trial.
Zhavoronkov links recorded ARDD 2026 sessions, among them Lilly's Kevin Duffin speaking on tirzepatide and aging clocks.
STAT
STAT's Pharmalittle notes Catherine Hanaway says Lilly broke its promise on discounted drugs to hospitals, alongside new results for a Lilly weight loss drug.
Nadolsky calls retatrutide the most powerful medicine likely to be approved soon for weight and type 2 diabetes, in his view.
Loading…